AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25214516 — intervention group
Group type: COMPARATOR
Intervention: No study treatment (Control)
Number of subjects: 65
Study 23392966 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatite-coated magnetite nanoparticles, injected intravenously or intraperitoneally at doses ranging from 100 to 2,500 mg/Kg.
Number of subjects: 0
Study 23392966 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatite-coated magnetite nanoparticles, size 8 ± 2 nm.
Number of subjects: 0
Study 22004767 — intervention group
Group type: EXPERIMENTAL
Intervention: Group based education, physiotherapy and peer support sessions, plus telephone contacts from T2DM volunteers
Number of subjects: 177
Study 22004767 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 177
Study 22004767 — intervention group
Group type: EXPERIMENTAL
Intervention: Group based education, physiotherapy and peer support sessions
Number of subjects: 177
Study 22004767 — intervention group
Group type: EXPERIMENTAL
Intervention: Group based education, physiotherapy and peer support sessions for IFG participants
Number of subjects: 177
Study 22004767 — intervention group
Group type: EXPERIMENTAL
Intervention: Group based education, physiotherapy and peer support sessions with longer follow-up (≥ 4 months)
Number of subjects: 177
Study 19280324 — intervention group
Group type: EXPERIMENTAL
Intervention: CRA13 administered in fed state
Number of subjects: 0
Study 19280324 — intervention group
Group type: COMPARATOR
Intervention: CRA13 administered in fasted state
Number of subjects: 0
Study 16911547 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced multidisciplinary care teams
Number of subjects: 1538
Study 15636272 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (one weight-based dose administered 60 minutes prior to treatment)
Number of subjects: 188
Study 15636272 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam with supplemental dosage (half the initial dose)
Number of subjects: 188
Study 15636272 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam augmented with nitrous oxide/oxygen mixtures (30-50%)
Number of subjects: 188
Study 11385379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwich operation (without cardiopulmonary bypass)
Number of subjects: 150
Study 11385379 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (control group)
Number of subjects: 150
Study 9265911 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 3500
Study 9265911 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 3500
Study 9265911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3500
Study 8501567 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer Edmonston-Zagreb (EZ) measles vaccine
Number of subjects: 384
Study 8501567 — intervention group
Group type: COMPARATOR
Intervention: Inactivated poliomyelitis vaccine and standard Schwarz vaccine
Number of subjects: 384
Study 3325185 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated mosquito nets
Number of subjects: 4
Study 3325185 — intervention group
Group type: COMPARATOR
Intervention: Unimpregnated mosquito nets
Number of subjects: 4
Study 30202998 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) alone or in combination with vitamin E
Number of subjects: 86
Study 30202998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 86
Study 30202998 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CoQ10 and Vitamin E
Number of subjects: 86
Study 30202998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 28566022 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery-Oriented Cognitive Therapy (CT-R)
Number of subjects: 60
Study 28566022 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 60
Study 26492115 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 52
Study 26492115 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 52
Study 23438670 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500mg oral daily until progression or severe toxicity
Number of subjects: 29
Study 23438670 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 29
Study 21942354 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort SMART)
Number of subjects: 654
Study 21942354 — intervention group
Group type: COMPARATOR
Intervention: Conventional best practice (CBP)
Number of subjects: 654
Study 18469236 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/d EPA + DHA esterified to phospholipid (PL-n-3) (300 mg/d phosphatidylserine)
Number of subjects: 60
Study 18469236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 60
Study 18469236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16484911 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet supplemented with eicosapentaenoic acid (EPA) and gamma-linolenic acid (GLA) for 14 days
Number of subjects: 100
Study 16484911 — intervention group
Group type: COMPARATOR
Intervention: Standard isonitrogenous, isocaloric enteral diet
Number of subjects: 100
Study 14602741 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasonography (CDU)
Number of subjects: 11
Study 14602741 — intervention group
Group type: COMPARATOR
Intervention: Gray-scale ultrasonography (GSU)
Number of subjects: 11
Study 14602741 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 11
Study 14602741 — intervention group
Group type: COMPARATOR
Intervention: Radionuclide imaging (RI)
Number of subjects: 11
Study 10337210 — intervention group
Group type: EXPERIMENTAL
Intervention: French cassoulet (CASS) 22.5 g/kg
Number of subjects: 8
Study 10337210 — intervention group
Group type: COMPARATOR
Intervention: International sauerkraut (CHOU) 22.5 g/kg
Number of subjects: 8
Study 8560291 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits offering social support to high-risk women
Number of subjects: 8
Study 8560291 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits providing medical care to women with complications
Number of subjects: 8
Study 8560291 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits (general)
Number of subjects: 8
Study 1770067 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity maintained (G)
Number of subjects: 0
Study 1770067 — intervention group
Group type: COMPARATOR
Intervention: Physical activity restricted (R)
Number of subjects: 0
Study 7104136 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anaesthesia with enflurane
Number of subjects: 0
Study 7104136 — intervention group
Group type: COMPARATOR
Intervention: i.v. fentanyl
Number of subjects: 0
Study 30410145 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week training on Biodex balance system
Number of subjects: 18
Study 30410145 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 18
Study 30410145 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups post-intervention
Number of subjects: 18
Study 27739405 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain computer interface (BCI) controlled functional electrical stimulation (FES)
Number of subjects: 12
Study 27739405 — intervention group
Group type: COMPARATOR
Intervention: Passive functional electrical stimulation (FES)
Number of subjects: 12
Study 25164450 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose group (acetated Ringer solution with 1.5% glucose)
Number of subjects: 22
Study 25164450 — intervention group
Group type: COMPARATOR
Intervention: Control group (acetated Ringer solution without glucose)
Number of subjects: 22
Study 25164450 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose group
Number of subjects: 22
Study 25164450 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 23140090 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg etoricoxib
Number of subjects: 66
Study 23140090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 20148656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015%
Number of subjects: 38
Study 20148656 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 38
Study 20148656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Tafluprost and Latanoprost
Number of subjects: 38
Study 20148656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost
Number of subjects: 38
Study 20148656 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 38
Study 18560239 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise protocol
Number of subjects: 12
Study 18560239 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 12
Study 16279144 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effects estimated within each trial assuming a common treatment effect across trials.
Number of subjects: 44
Study 16279144 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects methods used in analyses.
Number of subjects: 44
Study 16279144 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgrouping patients to investigate covariate-treatment interactions.
Number of subjects: 44
Study 16279144 — intervention group
Group type: EXPERIMENTAL
Intervention: Data inclusion from randomized patients.
Number of subjects: 44
Study 12460526 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent stage-matched intervention
Number of subjects: 2324
Study 12460526 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2324
Study 9788003 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg/day
Number of subjects: 0
Study 9788003 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 500 mg/day
Number of subjects: 0
Study 9788003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9788003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine 1 mg/kg
Number of subjects: 0
Study 9788003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine 2 mg/kg
Number of subjects: 0
Study 9788003 — intervention group
Group type: COMPARATOR
Intervention: Placebo for cocaine administration
Number of subjects: 0
Study 7637352 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐stat management
Number of subjects: 316
Study 7637352 — intervention group
Group type: COMPARATOR
Intervention: pH‐stat management
Number of subjects: 316
Study 7637352 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass group
Number of subjects: 316
Study 7637352 — intervention group
Group type: COMPARATOR
Intervention: Major surgery cohort
Number of subjects: 316
Study 2198928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (10 mg/kg/day)
Number of subjects: 27
Study 2198928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2198928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 27
Study 832447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC) 0.022 mg/kg
Number of subjects: 10
Study 832447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC) 0.044 mg/kg
Number of subjects: 10
Study 832447 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.157 mg/kg
Number of subjects: 10
Study 832447 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Ringer's lactate)
Number of subjects: 10
Study 31042670 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Number of subjects: 70
Study 31042670 — intervention group
Group type: COMPARATOR
Intervention: Healthy control diet
Number of subjects: 70
Study 27712113 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron IV (0.75 mg)
Number of subjects: 10
Study 27712113 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron IV (0.75 mg) and hydroxyzine PO (100 mg)
Number of subjects: 10
Study 27712113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26027624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) cardiac rehabilitation program, 3 weekly sessions for 12 weeks.
Number of subjects: 61
Study 26027624 — intervention group
Group type: COMPARATOR
Intervention: Full-body stretching exercises (control group), 3 weekly sessions for 12 weeks.
Number of subjects: 61
Study 23568480 — intervention group
Group type: EXPERIMENTAL
Intervention: uPA/PAI-1 testing
Number of subjects: 0
Study 23568480 — intervention group
Group type: COMPARATOR
Intervention: All-CTX strategy
Number of subjects: 0
Study 23568480 — intervention group
Group type: COMPARATOR
Intervention: No-CTX strategy
Number of subjects: 0
Study 21886066 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy and physiotherapy
Number of subjects: 60
Study 21886066 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 60
Study 19054177 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial group nursing intervention
Number of subjects: 235
Study 17245770 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS-based method
Number of subjects: 25
Study 17245770 — intervention group
Group type: COMPARATOR
Intervention: Standard method
Number of subjects: 25
Study 15301901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium administration
Number of subjects: 0
Study 15301901 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium administration to replenish low serum magnesium concentrations
Number of subjects: 0
Study 15301901 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate for treatment of torsade de pointes
Number of subjects: 0
Study 11702324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 283 micrograms (low dose, LD)
Number of subjects: 120
Study 11702324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 566 micrograms (high dose, HD)
Number of subjects: 120
Study 11702324 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydromorphone 283 micrograms and metamizole 50 mg (low dose hydromorphone + metamizole, LM)
Number of subjects: 120
Study 9135694 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily)
Number of subjects: 28
Study 9135694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7756153 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MMF)
Number of subjects: 15
Study 7756153 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone-17-valerate (BM-17-valerate)
Number of subjects: 15
Study 7756153 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 15
Study 2218190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of therapies with independent activity
Number of subjects: 0
Study 2218190 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of therapy to patients in a disease-free (remission) state
Number of subjects: 0
Study 75392 — intervention group
Group type: EXPERIMENTAL
Intervention: Flufenamic acid (200 mg three times a day)
Number of subjects: 44
Study 31842394 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 70
Study 31842394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 28337705 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids plus antioxidant vitamin supplementation
Number of subjects: 2
Study 28337705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 28337705 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented/POAF
Number of subjects: 2
Study 23853211 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 1650
Study 23853211 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Spectral Imaging Chromoendoscopy (FICE)
Number of subjects: 1650
Study 23853211 — intervention group
Group type: COMPARATOR
Intervention: White Light (WL)
Number of subjects: 1650
Study 22618211 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm-wrapped ileostomies
Number of subjects: 22
Study 22618211 — intervention group
Group type: COMPARATOR
Intervention: Conventional ileostomies
Number of subjects: 22
Study 22618211 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm stoma patients
Number of subjects: 22
Study 22618211 — intervention group
Group type: COMPARATOR
Intervention: Conventional stoma patients
Number of subjects: 22
Study 22618211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 20139661 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical exercise for 12 months
Number of subjects: 105
Study 18486224 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve decompression surgery (n = 127)
Number of subjects: 418
Study 18486224 — intervention group
Group type: COMPARATOR
Intervention: Careful follow‐up (n = 131)
Number of subjects: 418
Study 18486224 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (fellow nonstudy eyes)
Number of subjects: 418
Study 18486224 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (change in visual acuity)
Number of subjects: 418
Study 16162259 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fibre EMG (SFEMG) in migraine patients with aura
Number of subjects: 26
Study 16162259 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fibre EMG (SFEMG) in migraine patients with visual aura
Number of subjects: 26
Study 16162259 — intervention group
Group type: COMPARATOR
Intervention: Single-fibre EMG (SFEMG) in healthy controls
Number of subjects: 26
Study 16162259 — intervention group
Group type: COMPARATOR
Intervention: Single-fibre EMG (SFEMG) in migraine without aura
Number of subjects: 26
Study 12552492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie normoproteinic diet
Number of subjects: 30
Study 12552492 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary intake (Control)
Number of subjects: 30
Study 10379482 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alfa (6 MU t.i.w.) plus ribavirin (1000 mg/daily)
Number of subjects: 88
Study 10379482 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alfa alone (6 MU t.i.w.)
Number of subjects: 88
Study 10379482 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alfa plus ribavirin
Number of subjects: 88
Study 7675230 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegretol-XR 200-mg tablets every 12 hours
Number of subjects: 96
Study 7675230 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegretol 200-mg tablets three or four times daily
Number of subjects: 96
Study 2275837 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal composite restoration
Number of subjects: 103
Study 2275837 — intervention group
Group type: COMPARATOR
Intervention: Amalgam restoration
Number of subjects: 103
Study 2275837 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 103
Study 7222869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervically applied Prostaglandin F2 alpha Gel
Number of subjects: 124
Study 7222869 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 124
Study 31837079 — intervention group
Group type: EXPERIMENTAL
Intervention: DISCO
Number of subjects: 130
Study 30730438 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Number of subjects: 882
Study 30730438 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy in patients with intracranial pressure monitoring
Number of subjects: 882
Study 30730438 — intervention group
Group type: EXPERIMENTAL
Intervention: Single occurrence of mean arterial pressure < 65 mm Hg
Number of subjects: 882
Study 30730438 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure > 180 mm Hg
Number of subjects: 882
Study 27334444 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help intervention
Number of subjects: 260
Study 27334444 — intervention group
Group type: COMPARATOR
Intervention: Control condition (treatment as usual + online psychoeducation about depression)
Number of subjects: 260
Study 25827850 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation (BSC) intervention delivered by mental health specialists
Number of subjects: 97
Study 25827850 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 97
Study 25827850 — intervention group
Group type: EXPERIMENTAL
Intervention: BSC intervention
Number of subjects: 97
Study 25827850 — intervention group
Group type: COMPARATOR
Intervention: BSC intervention and usual GP care
Number of subjects: 97
Study 23374729 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% PRO2000 gel
Number of subjects: 544
Study 23374729 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 544
Study 21419286 — intervention group
Group type: EXPERIMENTAL
Intervention: IN ketorolac
Number of subjects: 22
Study 21419286 — intervention group
Group type: COMPARATOR
Intervention: IN placebo
Number of subjects: 22
Study 19165757 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning-centered intervention
Number of subjects: 109
Study 19165757 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (Control)
Number of subjects: 109
Study 17823418 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly strength training for 2 years
Number of subjects: 164
Study 17823418 — intervention group
Group type: COMPARATOR
Intervention: Standard care (brochures recommending aerobic exercise)
Number of subjects: 164
Study 15520425 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video about colorectal cancer and screening options (n = 450)
Number of subjects: 938
Study 15520425 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 488)
Number of subjects: 938
Study 11116286 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedisamil
Number of subjects: 0
Study 11116286 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 0
Study 9491571 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental support at encoding
Number of subjects: 0
Study 9491571 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental support at retrieval
Number of subjects: 0